Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479912 | 1.00 | HCAR1 (0.37) | HCAR1JAK1JAK2AURKAPRKCA | |
| SCHEMBL29479926 | 0.98 | JAK1 (0.39) | HCAR1JAK1JAK2AURKAPRKCA | |
| SCHEMBL21670412 | 0.98 | JAK1 (0.39) | HCAR1JAK1JAK2AURKAPRKCA | |
| SCHEMBL21670390 | 0.95 | JAK1 (0.34) | HCAR1JAK1JAK2AURKAPRKCA | |
| SCHEMBL29479916 | 0.95 | JAK1 (0.34) | HCAR1JAK1JAK2AURKAPRKCA | |
| SCHEMBL22070041 | 0.76 | EZH2 (0.34) | AURKA | |
| SCHEMBL29479924 | 0.75 | DPP4 (0.34) | ADORA2A | |
| SCHEMBL21670393 | 0.75 | GSK3A (0.30) | ADORA2AADORA1 | |
| SCHEMBL21670410 | 0.75 | DPP4 (0.34) | ADORA2A | |
| SCHEMBL29479928 | 0.75 | GSK3A (0.30) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| CN-114213421-A | 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109803972-B | 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | HCAR1 4339/4885JAK1 204/4885JAK2 398/4885 |
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | CDK4, CDK2, CDKL1 | HCAR1 4339/4885JAK1 204/4885JAK2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.